Research programme: toxin-induced sepsis therapies - VGX Pharmaceuticals
Latest Information Update: 12 Aug 2009
At a glance
- Originator VGX Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Sepsis
Most Recent Events
- 12 Aug 2009 Discontinued for Sepsis in USA (unspecified route)
- 12 Sep 2007 No development reported for Sepsis in USA (unspecified route)